This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
- The company cannot recommend any practices, procedures, or usage of IMAAVY that deviate from the approved labeling.
- In the overall VIVACITY-MG3 efficacy analysis population at week 24, patients receiving IMAAVY + standard of care (SOC) showed greater improvement in ocular Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores vs placebo (PBO) + SOC1:
- The odds ratio (OR) of achieving a ≥1-point improvement was 1.603 for the double vision MG-ADL item (95% confidence interval [CI]: 0.905-2.841) and 1.843 for the eyelid droop MG-ADL item (95% CI: 1.055-3.217).
- The OR of achieving a ≥2-point improvement in the overall MG-ADL-ocular domain was 2.88 (95% CI: 1.526-5.436).
- In the moderate-to-severe ocular manifestation (MSOM) population of the
VIVACITY-MG3 trial, the least squares (LS) mean (standard error [SE]) change from baseline in MG-ADL total score was -4.71 (0.50) with IMAAVY and -3.24 (0.50) with PBO. The median (interquartile range [IQR]) change from baseline in MG-ADL ocular domain score was -2.00 (-3.0 to -0.5) with IMAAVY and -1.00 (-1.5 to 0.0) with PBO.2
CLINICAL DATA
VIVACITY-MG3
Farmakidis et al (2025)1 conducted a post-hoc analysis of VIVACITY-MG3 to evaluate if changes in MG-ADL-total score with IMAAVY + SOC vs PBO + SOC were driven by individual items, domains, or distinct muscle function groups. Claeys et al (2026)2 conducted a post-hoc analysis of VIVACITY-MG3 to evaluate the efficacy of IMAAVY vs PBO in a subgroup of patients with generalized myasthenia gravis (gMG) and MSOM.
Study Design/Methods
- The VIVACITY-MG3 study evaluated the efficacy and safety of IMAAVY in adults with gMG in a phase 3, randomized, multicenter, double-blind, PBO-controlled study.3
- Patients (≥18 years of age) with anti-acetylcholine receptor (AChR), muscle-specific tyrosine kinase (MuSK), or low-density lipoprotein receptor 4 (LRP4) antibody-positive or seronegative (in all countries except France) gMG (Myasthenia Gravis Foundation of America [MGFA] class IIa-IVb) were included in the study.3
- Eligible patients had MG-ADL scores of ≥6 at both screening and baseline.2
- The safety analysis population included all randomized patients who received ≥1 dose (partial or complete) of any study treatment in the double-blind phase.3
- The efficacy analysis population included all patients from the safety analysis set who had anti-AChR, anti-MuSK or anti-LRP4 antibody positive gMG.3
- The study consisted of a ≤4-week screening phase, followed by a 24-week,
double-blind, PBO-controlled treatment phase, a variable-duration, open-label extension phase, and a safety follow-up at 8 weeks after the last infusion.3- Patients who withdrew or discontinued after receiving any amount of the study intervention were required to complete a safety follow-up assessment at 8 weeks after the last dose.
- Eligible patients were randomized (1:1) to receive either a loading dose of intravenous IMAAVY 30 mg/kg at week 0, followed by 15 mg/kg every 2 weeks (Q2W) or matching PBO through week 24 in addition to SOC therapy.3
- The MG-ADL scale includes two items in the ocular domain (double vision and eyelid droop), each scored from 0 to 3 to assess eye-related symptoms in myasthenia gravis (0: normal; 1: occurs, but not daily; 2: daily, but not constant; 3: constant).1
- In the Farmakidis et al post-hoc analysis, mean change from baseline in the ocular
MG-ADL domain and change of ≥1-point on MG-ADL items were evaluated.1 - In the Claeys et al post-hoc analysis, the MSOM population was defined as patients with a baseline score of ≥2 points on either the diplopia or ptosis items of the MG-ADL scale.2
- The endpoints assessed change from baseline at week 24 in MG-ADL total score,
MG-ADL ocular domain score, and MG-ADL item scores for diplopia and ptosis; the proportions of patients achieving MG-ADL minimum clinical improvement (MCI) and a ≥2-point within-patient improvement in MG-ADL ocular domain score; and the proportions of patients sustaining ≥2-point improvements in MG-ADL total and ocular domain scores over 24 weeks. - Change from baseline in quantitative myasthenia gravis (QMG) total and ocular domain scores, achievement of QMG MCI (≥3-point improvement), and sustained QMG MCI responses over 24 weeks were also assessed.
Results
MG-ADL Item Outcomes (Ocular Domain)
Baseline MG-ADL Item Score Distribution (Ocular Domain)1
|
|
|
|---|
|
|
|
|
|---|
0
| 26.3
| 25.0
| 17.1
| 19.7
|
1
| 22.4
| 35.5
| 21.1
| 27.6
|
2
| 27.6
| 27.6
| 40.8
| 32.9
|
3
| 23.7
| 11.8
| 21.1
| 19.7
|
Abbreviations: MG-ADL, Myasthenia Gravis-Activities of Daily Living; PBO, placebo; SOC, standard of care.
|
- At week 24, patients receiving IMAAVY + SOC were more likely to achieve a ≥1-point improvement in ocular MG-ADL items compared to PBO + SOC1:
- Double vision: OR, 1.603 (95% CI: 0.905-2.841)
- Eyelid droop: OR, 1.843 (95% CI: 1.055-3.217)
- At week 24, patients receiving IMAAVY + SOC showed numerically greater improvement in the ocular MG-ADL domain, with a mean change from baseline of -1.3 vs -0.6, and a significantly higher likelihood of achieving a ≥2-point improvement in this domain (OR, 2.88; 95% CI: 1.526-5.436) compared to PBO + SOC.1
Clinical Outcomes in MSOM Subgroup
- At baseline, patients in the MSOM subgroup receiving IMAAVY (n=54) and PBO (n=51) were comparable except for MG-ADL-ocular and QMG ocular scores.2 See Table: Baseline and Demographics.
Baseline and Demographics2 |
|
|
|---|
Age, years, mean (SD)
| 52.5 (15.6)
| 53.5 (16.8)
|
Female, n (%)
| 34 (63.0)
| 28 (54.9)
|
Race, n (%)
|
Asian
| 16 (29.6)
| 17 (33.3)
|
Black or African American
| 1 (1.9)
| 1 (2.0)
|
White
| 34 (63.0)
| 31 (60.8)
|
Other or not reported
| 3 (5.6)
| 2 (3.9)
|
BMI, kg/m2, mean (SD)
| 27.6 (5.6)
| 29.2 (5.8)
|
Duration of MG (years), mean (SD)
| 7.3 (8.0)
| 9.2 (8.9)
|
MG-ADL-total, mean (SD)
| 10.1 (2.8)
| 9.4 (1.9)a
|
MG-ADL-ocular, mean (SD)
| 4.1 (1.2)
| 3.5 (1.0)
|
MG-ADL diplopia, mean (SD)
| 2.0 (1.0)
| 1.5 (1.0)
|
MG-ADL ptosis, mean (SD)
| 2.2 (0.7)
| 1.9 (0.8)
|
QMG total, mean (SD)b
| 15.9 (5.1)
| 16.0 (4.9)
|
QMG ocular domain, mean (SD)b
| 4.9 (1.8)
| 4.3 (1.7)
|
MGFA classes, n (%)
|
I
| 1 (1.9)
| 0
|
IIa
| 5 (9.3)
| 7 (13.7)
|
IIb
| 9 (16.7)
| 7 (13.7)
|
IIIa
| 23 (42.6)
| 17 (33.3)
|
IIIb
| 10 (18.5)
| 11 (21.6)
|
Iva
| 2 (3.7)
| 7 (13.7)
|
IVb
| 4 (7.4)
| 2 (3.9)
|
Abbreviations: BMI, body mass index; MG, myasthenia gravis; MG-ADL, Myasthenia Gravis-Activities of Daily Living; MGFA, Myasthenia Gravis Foundation of America; PBO, placebo; QMG, Quantitative Myasthenia Gravis; SD, standard deviation. an=50. bn=52 for IMAAVY group; n=50 for PBO group.
|
Myasthenia Gravis Activities of Daily Living
Change from Baseline in MG-ADL Total Score and Ocular Outcomes at Week 242
|
|
|
|
|---|
| -4.71 (0.50)
| -3.24 (0.50)
| 0.042a
|
| -2.00 (-3.0 to -0.5)
| -1.00 (-1.5 to 0.0)
| 0.024a
|
MG-ADL diplopia, median (IQR)
| -1.00 (-1.0 to 0.0)
| -0.00 (-0.5 to 0.0)
| 0.057a
|
MG-ADL ptosis score, median (IQR)
| -1.00 (-2.0 to 0.0)
| -0.50 (-1.0 to 0.0)
| 0.101a
|
Abbreviations: IQR, interquartile range; LS, least squares; MG-ADL, Myasthenia Gravis-Activities of Daily Living; PBO, placebo; SE, standard error. aThese endpoints were not adjusted for multiple comparisons. Therefore, the P-values displayed are nominal, and statistical significance has not been established.
|
- At week 24, the proportion of patients achieving MG-ADL MCI was 64.8% in the IMAAVY group and 47.1% in the PBO group.
- The OR (95% CI) for achieving MG-ADL MCI was 4.10 (1.42-11.86) with IMAAVY vs PBO. Over the 24-week treatment period, OR (95% CI) for achieving MG-ADL MCI was 1.79 (0.95-3.37) with IMAAVY vs PBO.
- Sustained meaningful within-person improvement (MWPI, a ≥2-point improvement in MG-ADL total score) is presented in Table: Sustained MG-ADL Total Score ≥2-Point Improvement.
Sustained MG-ADL Total Score ≥2-Point Improvement2
|
|
|
|
|
|---|
≥8 weeks
| 60.8
| 68.5
| 1.40 (0.63-3.14)
| 0.422a
|
≥12 weeks
| 43.1
| 63.0
| 2.24 (1.02-4.90)
| 0.051a
|
≥16 weeks
| 33.3
| 55.6
| 2.50 (1.13-5.52)
| 0.031a
|
≥20 weeks
| 31.4
| 48.1
| 2.03 (0.92-4.51)
| 0.111a
|
Abbreviations: CI, confidence interval; MG-ADL, Myasthenia Gravis-Activities of Daily Living; OR, odds ratio; PBO, placebo. Note: P-values are based on Fisher’s exact test. aThese endpoints were not adjusted for multiple comparisons. Therefore, the P-values displayed are nominal, and statistical significance has not been established.
|
- At week 24, the proportion of patients achieving a ≥2-point within-person improvement in MG-ADL ocular domain score was 40.7% in the IMAAVY group and 19.6% in the PBO group.
- At week 24, OR (95% CI) for achieving a ≥2-point within-person improvement in MG-ADL ocular domain score was 3.47 (1.34-8.97) with IMAAVY vs PBO. Over the 24-week treatment period, OR (95% CI) for achieving a ≥2-point within-person improvement in MG-ADL ocular domain score was 2.74 (1.36-5.52) with IMAAVY vs PBO.
- Sustained MWPI (a ≥2-point improvement in MG-ADL ocular domain score) is presented in Table: Sustained MG-ADL Ocular Domain ≥2-Point Improvement.
Sustained MG-ADL Ocular Domain ≥2-Point Improvement2
|
|
|
|
|
|---|
≥8 weeks
| 23.5
| 38.9
| 2.07 (0.89-4.83)
| 0.098a
|
≥12 weeks
| 17.6
| 35.2
| 2.53 (1.02-6.30)
| 0.049a
|
≥16 weeks
| 13.7
| 25.9
| 2.20 (0.81-6.00)
| 0.146a
|
≥20 weeks
| 9.8
| 20.4
| 2.35 (0.76-7.33)
| 0.177a
|
Abbreviations: CI, confidence interval; MG-ADL, Myasthenia Gravis-Activities of Daily Living; OR, odds ratio; PBO, placebo. Note: P-values are based on Fisher’s exact test. aThese endpoints were not adjusted for multiple comparisons. Therefore, the P-values displayed are nominal, and statistical significance has not been established.
|
- At week 24, a ≥1-point improvement in the MG-ADL diplopia item was achieved by 51.2% of patients in the IMAAVY group and 24.4% of patients in the PBO group (OR [95% CI]: 3.26 [1.27-8.33]).
- At week 24, a ≥1-point improvement in the MG-ADL ptosis item was achieved by 56.1% of patients in the IMAAVY group and 43.9% of patients in the PBO group (OR [95% CI]: 1.63 [0.68-3.91]).
Quantitative Myasthenia Gravis
- At week 24, QMG MCI was achieved by 37.0% of patients in the IMAAVY group and 23.5% of patients in the PBO group (OR [95% CI]: 3.01 [1.19-7.66]).2
- Throughout the 24-week treatment period, OR (95% CI) for achieving QMG MCI was 3.75 (1.93-7.29).
- A greater percentage of patients receiving IMAAVY than PBO achieved sustained QMG total score MCI responses (a ≥3-point improvement) for ≥8, ≥12, ≥16, and ≥20 consecutive weeks.
- At week 24, the median (IQR) change from baseline in QMG ocular domain score was
-2.00 (-3.0 to 0.0) in the IMAAVY group and -0.25 (-1.5 to 0.5) in the PBO group.
Safety (Overall VIVACITY-MG3 Cohort)
- The proportion of patients who reported related adverse events (AEs), per investigator assessment, was 29% in both the IMAAVY (28/98) and PBO (28/98) groups.3
- Any serious adverse events were reported in 9% (9/98) and 14% (14/98) of patients in the IMAAVY and PBO groups, respectively.3
- The most common AEs occurring in ≥10% of patients in the IMAAVY group compared to the PBO group were coronavirus disease 2019 (COVID-19)-associated AEs (15% vs 12%), headache (14% vs 17%), muscle spasms (12% vs 3%), myasthenia gravis (12% vs 12%), and peripheral edema (12% vs 2%).3,4
Literature Search
A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 29 September 2026.
| 1 | Farmakidis C, Gandhi K, Ait-Tihyaty M, et al. Symptom severity assessment using MG-ADL items and domains in a 24-week, phase 3 study (Vivacity) of nipocalimab in generalized myasthenia gravis. Poster presented at: Myasthenia Gravis Foundation of America (MGFA) Scientific Session of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting; October 15-18, 2024; Savanah, Georgia. |
| 2 | Claeys AG, Yang H, Gandhi K, et al. Efficacy of nipocalimab in patients with moderate-to-severe ocular symptoms of generalized myasthenia gravis in the phase 3 Vivacity-MG3 study. Expert Opinion on Biological Therapy. 26(9):997-1007. |
| 3 | Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116. |
| 4 | Data on File. Nipocalimab Company Core Data Sheet v005. Janssen Research & Development, LLC. EDMS-RIM-1007434; 2026. |